Clinical Trial Update: ATA-200 Gene Therapy Trial in Patients With LGMDR5 [Phase 1]

View source ↗

Summary

The ATA-200 gene therapy trial for LGMD type 2C (Limb-girdle muscular dystrophy type 2C) is in Phase 1 and currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Limb-girdle Muscular Dystrophy Type 2c

Drugs mentioned

• ATA-200 (ATA-200 gene therapy)

Snippet

Sponsor: Atamyo Therapeutics | Conditions: LGMD2C | Phase 1 | Status: ACTIVE_NOT_RECRUITING